drugset
drugset / Trial / NCT03531710

An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311

NCT03531710 ↗

Phase 2 Terminated 34 enrolled United Neuroscience Ltd.
Non-randomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the long-term safety, tolerability and potential efficacy, patients who previously participated in V203-AD study (NCT02551809) will be eligible to participate in the extension study and will receive 3 or 5 doses of UB-311 within a 96-week treatment period followed by a 12-week follow-up period.

Timeline

Start
2018-08-10
Primary completion
2019-10-31
Completion
2019-10-31

Outcome

Outcome not reported

Stopped: “United Neuroscience has decided to terminate V203-AD-EXT study based on a treatment assignment error”

Drugs

EvaluationDrugModalityDoseRoute
Subject UB-311 Vaccine — Intramuscular

Indications

Alzheimer disease